



WHERE IS THE NORTH AMERICAN CBD MARKET?

VANCOUVER, BC, Tuesday March 26, 2019 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the “Company”) provides overview of the North American Cannabidiol (CBD) industry. The CBD market is projected to be worth more than \$20 billion by 2022, according to research firm Brightfield Group.

As North America and most parts of the industrialized world look to legalize THC based cannabis products, the world of Hemp-based products has taken on a revival. Not so much for food-based products, but for the specific extracted oils from the plant that contain high concentrations of Cannabidiol or “CBD”.

In Canada, the Canadian Cannabis Act clears the way for whole hemp plant utilization. Industrial hemp licenses would authorize the intra-industry sale of leaves, flowers and branches (or the whole plant). That means licensed industrial hemp producers could sell the flower to someone who has permits to process and sell CBD-based products from plants that contain less than 0.3% THC in Canada and the United States. The newly enacted Farm Bill in the United States has created opportunities within the CBD sector as well, “... *any cannabinoid that is derived from hemp would be considered legal, provided that the production meets all of the federal regulations, state level regulations, and other guidelines in a manner that is consistent with the Farm Bill...*”.

The value of Hemp for the Company is not necessarily in the raw biomass but rather in the extracted oils and resulting CBD based products. Biomass is generally worth .10 – .20 cents per gram, CBD isolate market price is around \$7.5/ gram, 50x more price dense per volume. With its Hemp production facility near completion in Nevada, the Company is ready for the demand for its branded hemp-derived CBD based products.

EviTrade continues to fulfill its commitment to elevate the human condition through advanced medical solutions and effective health and wellness research and products.

Contact:

EVITRADE Health Systems Corp.
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com or ceo@auxellence.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

About EVITRADE Health (CSE: EVA, OTCQB: EVAHF)

EVITRADE Health Systems Corp. (formerly, Auxellence Health Corporation), is a technology company specializing in the Health and Life Sciences sector looking to deliver effective personalized health solutions with a higher degree of predictability and consistency.

The Company is focused on the following areas to help improve health: personalized medical care (including CBD usage monitoring and effects on the cardiovascular system), molecular biology, nutraceutical solutions and genetic tailoring.

Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcmarkets.com/stock/EVAHF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.